Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

Table 2 List of the most frequent BCR-ABL1 kinase domain mutations resistant to ATP-competitive inhibitors reported in published studies

imatinib						nilotinib	dasatinib	bosutinib	ponatinib
M237V	L273M	F311L	E355D/G	V379I	A397P	Y253F/H	V299L	V299L	T315M
M244V	E275K/Q	T315I	F359V/I/C	A380T	S417F/Y	E255K/V	T315I	T315I	T315L
L248R	D276G	F317L/V/I/C	D363Y	F382L	I418S/V	T315I	F317L/V/I/C	?
G250E/R	T277A	F359V/I/C	L364I	L384M	S438C	F359V/I/C
Q252R/H	E279K	Y342H	A365V	L387M/F	E453G/K
Y253F/H	V280A/I	M343T	L370P	M388L	E459K/V
E255K/V	V289A	A344V	V371A	Y393C	P480L
E258D	V299L	M351T	E373K	H396R/P	F486S

The T315I is highlighted in bold and underlined. The question mark indicates that finding novel resistant mutations in the near future cannot be excluded

ISSN: 1476-4598